Evidence supporting the use of: Bifobacterium (mixed)
For the health condition: Multiple Sclerosis

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Bifidobacterium (mixed) is being investigated for its potential to support patients with Multiple Sclerosis (MS), primarily due to its role in modulating gut microbiota and immune responses. Emerging scientific studies have demonstrated that individuals with MS often display altered gut microbiota profiles, including reduced levels of Bifidobacterium species. Preclinical research and small-scale human studies suggest that supplementation with Bifidobacterium may help restore a healthier gut microbiome, potentially reducing systemic inflammation and modulating immune activity implicated in MS pathogenesis.

For example, a 2017 pilot randomized controlled trial (Frontiers in Immunology, 2017) showed that probiotic supplementation, including Bifidobacterium species, resulted in improved anti-inflammatory cytokine profiles and decreased markers of inflammation in MS patients. Another small study (Cell Reports, 2021) found that probiotic supplementation with Bifidobacterium modulated gut microbiota composition and was associated with beneficial immune changes. However, these studies are limited by small sample sizes, short durations, and variations in probiotic formulations.

Overall, while the rationale for using Bifidobacterium in MS is supported by early scientific findings and the known gut-brain-immune axis, robust clinical evidence is lacking. There is currently insufficient high-quality data to recommend Bifidobacterium as a standard adjunct therapy for MS, but ongoing research may further clarify its potential benefits.

More about Bifobacterium (mixed)
More about Multiple Sclerosis

Products containing Bifobacterium (mixed)

We currently have no products on Vitabase that contain this ingredient.